SEARCH

SEARCH BY CITATION

References

  • 1
    Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 0: 8019.
  • 2
    Czubayko F, Smith RV, Chung HC, Wellstein A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 1994; 269: 282438.
  • 3
    Lobb RR, Alderman EM, Fett JW. Induction of angiogenesis by bovine brain derived class I heparin-binding growth factor. Biochemistry 1985; 24: 496973.
  • 4
    Risau WH, Drexler V, Mironov A, Smits A, Siegbahn A, Funa K, Heldin CH. Platelet derived growth factor is angiogenic in vivo. Growth Factors 1992; 7: 2616.
  • 5
    Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF β-receptors. J Cell Biol 1994; 125: 91728.
  • 6
    Ishikawa F, Miyazono K, Hellman U, Wernstedt C, Haguwara K, Usuki K, Takaku F, Risau W, Heldin CH. Identification of angiogenic activity and the cloning and expressions of platelet-derived endothelial cell growth factor. Nature 1989; 338: 55762.
  • 7
    Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 12503.
  • 8
    Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. Transforming growth factor type-β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 416771.
  • 9
    Frater-Schroder M, Risau W, Hallmann R, Gautschi R, Bohlen P. Tumor necrosis factor type-α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 527781.
  • 10
    Fett JW, Strydom DJ, Lobb RF, Alderman EM, Bethune JL, Riordan JF, Vallee BL. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985; 24: 54806.
  • 11
    Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798801.
  • 12
    Ferrara N, Leung DW, Cachianes G, Winer J, Henzel WJ. Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. Methods Enzymol 1991; 198: 391405.
  • 13
    Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992; 13: 1832.
  • 14
    Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 130912.
  • 15
    Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculostellate cells. Proc Natl Acad Sci USA 1989; 86: 73115.
  • 16
    Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 180614.
  • 17
    Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 21120.
  • 18
    Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 1993; 264: C9951002.
  • 19
    Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham A. The human gene for vascular endothelial growth factor. J Biol Chem 1991; 266: 1194754.
  • 20
    Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 414956.
  • 21
    Möhle R, Green D, Moore MAS, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 6638.
  • 22
    Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 95664.
  • 23
    Hanatani M, Tanaka Y, Kondo S, Ohmori I, Suzuki H. Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/vascular permeability factor in human serum. Biosci Biotech Biochem 1995; 59: 19589.
  • 24
    Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17: 18590.
  • 25
    Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 6169.
  • 26
    Deuel TF, Huang JS. Platelet-derived growth factor. Structure, function and roles in normal and transformed cells. J Clin Invest 1984; 74: 66976.
  • 27
    Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998; 275: H105461.
  • 28
    Packham MA, Nishizawa EE, Mustard JF. Response of platelets to tissue injury. Biochem Pharmacol 1968; 17 (Suppl.): 17184.
  • 29
    Nachman RL, Weksler B, Ferris B. Increased vascular permeability produced by human platelet granule cationic extract. J Clin Invest 1970; 49: 27481.
  • 30
    Nachman RL, Weksler B, Ferris B. Characterization of human platelet vascular permeability-enhancing activity. J Clin Invest 1972; 51: 54956.
  • 31
    Miyazono K, Okabe T, Urabe A, Yamanaka M, Takaku F. A platelet factor that stimulates the proliferation of vascular endothelial cells. Biochem Biophys Res Commun 1985; 126: 838.
  • 32
    Miyazono K, Heldin CH. High yield purification of platelet-derived endothelial cell growth factor: structural characterization and establishment of a specific antiserum. Biochemistry 1989; 28: 170410.
  • 33
    Liotta LA, Tryggvason K, Garbisa S, Hart IR, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 678.
  • 34
    Fessler LI, Duncan KG, Fessler JH, Salo T, Tryggvason K. Characterisation of the procollagen IV cleavage products produced by a specific tumor collagenase. J Biol Chem 1984; 259: 97839.
  • 35
    Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci 1990; 31: 177988.
  • 36
    Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72kDa progelatinase, and metalloproteinase inhibitor expression in human fibroblasts by transforming growth factor-β. J Biol Chem 1989; 264: 18609.
  • 37
    Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane collagen: degradation by migrating epithelial cells. Science 1983; 221: 2813.
  • 38
    Garbisa S, Ballin M, Daga-Gordini D, Fastelli G, Naturale M, Negro A, Semenzato G, Liotta LA. Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes. J Biol Chem 1986; 261: 236975.
  • 39
    Dvorak HF, Dvorak AM, Manseau EJ, Wiberg L, Churchill WH. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 1979; 62: 145972.